Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AME and PK of [14C]-AKB-9778 in Healthy Males
NCT02858271Phase 1Completed
- Sponsor
- Aerpio Therapeutics
- Start
- Jul 2016
- Primary completion
- Jul 2016
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of razuprotafib in diabetic macular edema (DME) and diabetic retinopathy (DR), sponsored by Aerpio Therapeutics. Primary endpoints: Percent of radioactive dose recovered in urine and feces at 7 days, Concentration of total radioactivity in blood and plasma at 7 days and 5 more. Started Jul 2016; status: completed.
02
Drugs
razuprotafib
03
Conditions
diabetic macular edema (DME)diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT02858271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02858271.